A Phase 3, Multicenter, Randomized, Two-Arm, Open-Label Study of Intermittent Oral Dosing of Roxadustat for the Treatment of Anemia in Japanese Erythropoiesis-Stimulating Agent-Naïve Chronic Kidney Disease Patients Not on Dialysis-Reference-Cited by-同舟云学术

A Phase 3, Multicenter, Randomized, Two-Arm, Open-Label Study of Intermittent Oral Dosing of Roxadustat for the Treatment of Anemia in Japanese Erythropoiesis-Stimulating Agent-Naïve Chronic Kidney Disease Patients Not on Dialysis

Published:2020 Issue:8 Volume:144 Page:372-382
ISSN:1660-8151
Container-title:Nephron
language:en
Short-container-title:Nephron

Author:

Akizawa Tadao,Yamaguchi Yusuke,Otsuka Tetsuro,Reusch Michael

Publisher

S. Karger AG

Reference18 articles.

1. Fishbane S, Spinowitz B. Update on anemia in ESRD and earlier stages of CKD: core curriculum 2018. Am J Kidney Dis. 2018;71(3):423–35.

2. Akizawa T, Okumura H, Alexandre AF, Fukushima A, Kiyabu G, Dorey J. Burden of anemia in chronic kidney disease patients in Japan: a literature review. Ther Apher Dial. 2018;22(5):444–56.

3. Del Vecchio L, Locatelli F. An overview on safety issues related to erythropoiesis-stimulating agents for the treatment of anaemia in patients with chronic kidney disease. Expert Opin Drug Saf. 2016;15(8):1021–30.

4. Johnson DW, Pollock CA, Macdougall IC. Erythropoiesis-stimulating agent hyporesponsiveness. Nephrology (Carlton). 2007;12(4):321–30.

5. Locatelli F, Del Vecchio L. Will there still be a role for the originator erythropoiesis-simulating agents after the biosimilars and the hypoxia-inducible factor stabilizers approval? Curr Opin Nephrol Hypertens. 2018;27(5):339–44.

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Medicinal Chemistry Strategies for the Modification of Bioactive Natural Products;Molecules;2024-02-02

2. Roxadustat and Oral Iron Absorption in Chinese Patients with Anemia of Chronic Kidney Disease: A Randomized, Open-Label, Phase 4 Study (ALTAI);Advances in Therapy;2024-01-27

3. Hypoxia inducible factors inhibit respiratory syncytial virus infection by modulation of nucleolin expression;iScience;2024-01

4. Hypoxia inducible factors inhibit respiratory syncytial virus infection by modulation of nucleolin expression;2023-11-02

5. Novel anemia therapies in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference;Kidney International;2023-10